A 14 week, randomized, double-blind, placebo-controlled trial of pregabalin twice daily in patients with fibromyalgia

Trial Profile

A 14 week, randomized, double-blind, placebo-controlled trial of pregabalin twice daily in patients with fibromyalgia

Completed
Phase of Trial: Phase III

Latest Information Update: 14 May 2016

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Fibromyalgia
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 May 2016 Results of a pooled analysis from NCT00645398, NCT00230776, NCT00333866 trials (n=2228) presented at the 35th Annual Scientific Meeting of the American Pain Society
    • 03 May 2014 Results from a pooled analysis presented at the 33rd Annual Scientific Meeting of the American Pain Society.
    • 24 Sep 2008 Actual patient number changed from 986 to 755 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top